IL-33 serves as a pro-tumorigenic cytokine supporting carcinogenesis and influencing reduced antitumor immunity, as demonstrated by the increased expression of IL33 mRNA and proteins within primary tumors in animal model of breast cancer (Wasmer and Krebs, 2017). Here, IL33 is linked to breast cancer.